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Abstract
Cirrhosis is the main complication of chronic liver disea-
se, leads to progressive liver function impairment and is 
the main risk factor for the development of liver cancer. 
Liver failure at endstage cirrhosis is associated with 
increased mortality with liver transplantation as the 
only possible treatment at this stage. The pathogenesis 
of liver cirrhosis is not completely elucidated. Although 
the common factors leading to liver injury, such as 
viral hepatitis, alcohol consume or fatty liver disease 
can be identified in the majority of patients a small 
percentage of patients have no apparent risk factors. 
Moreover given the same risk factors, some patients 
progress to cirrhosis whereas others have a benign 
course, the reason remains unclear. In order to develop 
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new diagnostic and therapeutic tools, it is s essential 
to understand the pathogenesis of cirrhosis. The 
identification of genetic risk factors associated with 
cirrhosis is one of the possible approach to achieve 
these goal. In the past years several studies have 
supported the role of telomere shortening and cirrhosis. 
In the recent year several studies on the relation 
between several single nucleotide polymorphism 
(SNPs) and cirrhosis have been published; it has been 
proposed also a cirrhosis risk score based on seven 
SNPs. Also epidemiological studies on identical twins 
and in different ethnic groups have been supporting the 
importance of the role of genetic risk factors. Finally 
in the very recent years it has been suggested that 
telomere shortening may represent a genetic risk factor 
for the development of cirrhosis.
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polymorphism; Gene mutation; Telomere; Telomerase
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Core tip: Common risk factors leading to chronic 
liver injury can be identified in most patients with 
cirrhosis, but approximately 5% of patients have no 
apparent risk factors. Understanding the pathogenesis 
of cirrhosis formation is essential to develop new 
diagnostic and therapeutic tools and for its prevention. 
The identification of genetic risk factors associated 
with cirrhosis is one of the possible way to approach 
this issue. Evidence supporting the role of genetic risk 
factors has been accumulating during the past years 
and recently it has been also suggested that telomere 
shortening may represent a genetic risk factor.
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CIRRHOSIS
Cirrhosis represents the main complication of  chronic 
liver disease[1-3], leads to progressive liver failure, even-
tually to hepatocarcinoma[4] and is associated with in-
creased mortality[5] with liver transplantation as the only 
possible therapeutic option at this stage. The patho-
genesis of  liver cirrhosis remains unclear and although 
the common risk factors, such as viral hepatitis, alcohol 
and non-alcoholic fatty liver disease (NAFLD) can be 
identified in the majority of  patients, there is a small 
percentage of  patients with no identifiable risk factors[6]. 
Moreover it is known that patients with the same risk 
factors present different clinical manifestations, some 
develop cirrhosis and hepatocarcinoma (HCC) others 
have a benign course, the reason of  the different 
evolution is not completely elucidated[7]. Understanding 
the complex pathogenesis of  cirrhosis is important for its 
prevention and to identify new diagnostic tools as well as 
new therapeutic options; one of  the possible approaches 
to this issue might be to understand the genetic bases of  
cirrhosis[8,9].
GENETIC CAUSES OF CIRRHOSIS
In the past years several studies have supported the role 
of  telomere shortening and cirrhosis.
In a recent study it was proposed a cirrhosis risk 
score (CRS) based on a panel of  seven single-nucleotide 
polymorphisms (SNPs) in six genes: AP3S2, AQP2, 
AZIN1, STXBP5L, TLR4, TRPM5 and in the intergenic 
region between DEGS1 and NVL for identifying the 
risk of  developing cirrhosis in Caucasian patients with 
chronic hepatitis C infection[10]. The CRS performance 
resulted even a better predictor of  cirrhosis than 
clinical factors. It is also been utilized and validated in 
another study on patients with hepatitis C virus (HCV) 
hepatitis[11], it was observed that host genetics defined 
by CRS, predict fibrosis progression and may help for 
prognostic evaluation and treatment decision.
Furthermore, in a study conducted on a large cohort 
of  patients with histologically proven NAFLD it was 
demonstrated that the PNPLA3 (patatin-like phospho-
lipase domain-containing protein 3) SNP rs738409 
was more frequent in patients with fibrosis[12]. It was 
also observed by Stickel et al[13], that the PNPLA3 SNP 
rs738409 was more frequent also in Caucasian patients 
with alcoholic cirrhosis.
Some SNPs have been associated to an increased 
susceptibility to liver cirrhosis also in HBV infected 
patients. It has been described a polymorphism of  the 
Glucose-Regulated Protein 78 (GRP78): rs430397 G>A. 
The Authors observed that HBV infected patients 
carrying the allele 430397A were more prone to develop 
liver cirrhosis compared to wild type patients[14].
Taken together these data suggest a genetic predis-
position to the development of  cirrhosis. The real contri-
bution of  these SNPs on the genetic predisposition is not 
yet elucidated. 
Finally data from epidemiologic studies reported 
difference in prevalence of  cryptogenic cirrhosis in 
different ethnic groups. 
A study by Browning et al[15] revealed that given the 
same prevalence of  diabetes in Hispanics and African 
Americans they had a different cryptogenic cirrhosis’ 
prevalence, respectively, 3-fold higher and 4-fold lower 
compared to European Americans; these finding not only 
indicate that this form of  cirrhosis is unexpectedly rare 
among Afro Americans, but indicate also that there is a 
different genetic predisposition among different ethnic 
groups. 
Also studies on twins show the same results. Data 
on monozygotic and dizygotic twins reported a genetic 
predisposition in developing alcoholism related disease. 
In fact it has been shown, for alcoholic psychosis and 
cirrhosis, a significantly greater concordance in mono-
zygotic twins-pairs compared to dizygotic twins-pairs 
(16.9% vs 5.3%)[16].
TELOMERE SHORTENING AND 
CIRRHOSIS
In addition to the results from SNP and epidemi-ological 
studies, recently it has been suggested that telomere 
shortening may represent a genetic risk factor for the 
development of  cirrhosis.
Telomeres consist of  repetitive DNA sequences 
(TTAGGG) located at the ends of  linear chromosomes. 
They function as a cap to stabilize and protect chromo-
somes from erosion and from being mistaken for double-
strand DNA breaks. During each cell division, telomeres 
shorten due to the ‘‘end-replication problem’’ that is 
the DNA polymerase’s inability to fully replicate the 3’ 
end of  chromosomes. Telomere attrition is avoided by 
telomerase that elongates telomere DNA after each cell 
division[17]. In conditions of  chronic liver injury there is 
a high cell turnover as a regeneration and repair process, 
telomeres become too short and the cell does not divide 
anymore, the mechanisms by which cell growth arrest is 
profibrogenic is not yet defined (Figure 1).
Several studies have investigated the relationship 
between cirrhosis and telomere shortening. Studies 
on humans showed that shortened telomere length in 
hepatocytes is correlated with degree of  fibrosis and it 
may be considered as a marker of  cirrhosis formation. 
In 1995 Kitada et al[18] demonstrated the relationship 
between telomere shortening and liver cirrhosis. They 
observed that telomere length was increasingly shorter 
in tissue from cirrhotic and chronic hepatitis livers and 
obviously shorter than normal liver tissue. Following 
studies confirmed that telomere length was related to the 
degree of  fibrosis, suggesting that it may contribute to 
the development of  cirrhosis[18-20].
Moreover, studies on telomerase-deficient mice 
provided experimental evidence that shortened telomeres, 
in response to chronic liver injury, are associated with 
impaired liver regeneration and accelerated cirrhosis 
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development. Restoration of  telomerase activity into the 
liver of  these mice resulted in reduction of  cirrhosis and 
improved liver function[21]. These findings suggest that 
reduced telomerase activity may contribute to cirrhosis 
development. Mutations in the telomerase complex genes 
have been implicated in rare human diseases characterized 
by accelerated telomere shortening and organ failure 
such as dyskeratosis congenita. Interestingly, patients 
suffering from these diseases showed an increased 
frequency of  liver pathologies including fibrosis and 
cirrhosis[22]. Recently, two studies have also investigated 
the frequency of  telomerase mutations in patients with 
sporadic cirrhosis compared to healthy controls[21,22]. 
Both studies screened patients for variation in the TERT 
and TERC genes. In the first study by Calado et al[23]. The 
Authors found missense mutations in the TERT and 
TERC genes. The frequency of  TERT gene mutations in 
cirrhotic patients was significantly greater than controls. 
Moreover cirrhosis was also associated with shorter 
telomeres in peripheral blood leukocytes. Finally, most 
TERT variants showed reduced telomerase activity in 
vitro. In the second study Hartmann et al[24]. Screened 
patients with sporadic cirrhosis and noncirrhotic controls 
for telomerase mutations. Of  note, control group was 
composed of  473 healthy individuals and 127 patients 
with chronic HCV infection who did not develop 
cirrhosis during a long follow-up. The data analysis 
revealed a significantly increased frequency of  telomerase 
mutations in the cirrhosis group compared to the control 
group. Again, TERT gene mutations in cirrhotic patients 
were associated with reduced telomerase activity in vitro 
and shorter telomeres in peripheral blood leukocytes 
compared to non-cirrhotic patients. Our group recently 
reported on the coexistence of  cryptogenic cirrhosis 
(CC) and IPF, not in the setting of  dyskeratosis con-
genita, and telomere dysfunction[25]. In our study was 
described a case of  a 48-year-old woman, diagnosed 
of  cryptogenic liver cirrhosis, idiopathic pulmonary 
fibrosis and diabetes. Both CC and IPF had a rapid 
progression and after eighteen months the patient died. 
Sequencing and mutation analysis of  TERT and TERC 
genes demonstrated the presence of  a heterozygous 
TERT mutation (L153M). The TERT L153M variant 
results in a change of  methionine for leucine at amino 
acid 153, in the protein region that seems to be involved 
in the template RNA and telomeric DNA binding. 
Furthermore, leukocyte telomere length was significantly 
shorter. Our case report gives further evidence of  telo-
mere involvement in liver disease progression and su-
ggests short telomere as genetic risk factor for cirr-
hosis. Moreover very recently our group reported on 
a similar case of  a 58 years old man who presented a 
short telomere syndrome: pulmonary fibrosis, mild bone 
marrow fibrosis and a liver cirrhosis. The patient was an 
active smoker and obese. He rapidly developed ascites 
and progression of  the pulmonary fibrosis, the patient 
became oxygen-dependent in few months. He presented 
a very short leukocyte telomere length and reduced 
telomerase activity compared to a group of  controls, but 
did not show any hTERT and hTERC genes mutations[26]. 
Since the prevalence of  telomerase mutations seems to 
be rather low in the general population, they may not 
be the major contributing factor to cirrhosis. Probably 
looking for telomerase genes mutations only, there is 
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Figure 1  Telomere shorten at each cell division, when they became critically short cellular signaling cascades are activated resulting in cell senescence 
or apoptosis.
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the risk to underestimate the real contribution of  the 
telomere system dysfunction to the development of  
cirrhosis. In fact other components of  the telomere 
complex such as dyskerin and the telomere binding 
proteins have been shown to be important for telomerase 
activity[27]. Mutations in these components can lead to an 
impairment of  telomere function; recently a mutation 
of  the binding protein TIN2 has been involved in the 
evolution of  aplastic anemia[28]. Finally also the mutations 
in the noncoding sequence of  TERC and TERC could 
be responsible for impairment in the expression of  
TERC and TERT. Probably the sequence analysis of  
all components of  the “telomere system or telosome” 
will reveal the real contribution of  telomere complex 
genes mutations to the development of  liver cirrhosis. 
Together, the current data would suggest that telomere 
attrition may play a role in the sequence of  events 
leading to cirrhosis. According to this view chronic liver 
injury induces hepatocyte regeneration and therefore 
an elevated cell turnover; hence increased telomere 
shortening and cell senescence. Eventually, if  the injury 
persists, other cells, such as stellate cells become activated 
leading to fibrogenesis[29]. Therefore telomerase muta-
tions might be considered as genetic risk factors for 
cirrhosis and telomere shortening as an important step in 
its pathogenesis. A clinical implication of  these findings 
would be the future use of  assay of  telomerase gene 
mutations in the selection and treatment of  patients 
with liver disease[7]. What is the relationship between 
cirrhosis, HCC and telomere complex dysfunction? Since 
carcinogenesis reactivate telomerase activity, it is not clear 
yet if  patients with telomerase mutations have a greater 
predisposition to develop HCC after cirrhosis[7]. More 
data and larger studies are needed to understand the real 
impact of  telomere dysfunction on HCC development. 
It is not known; neither is clear why some patients with 
cirrhosis will develop HCC relatively early in the natural 
history of  cirrhosis whereas others with more advanced 
stages of  liver dysfunction do not develop HCC; if  this 
could be related to telomere dysfunction needs to be 
investigated. Future studies with large number of  patients 
are needed to provide answers to these questions. 
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